Nurix Therapeutics | LinkedIn (original) (raw)

Biotechnology

San Francisco, CA 17,635 followers

Targeted protein degradation is only the beginning. Blazing a new path in medicine.

About us

Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.

Industry

Biotechnology

Company size

201-500 employees

Headquarters

San Francisco, CA

Type

Public Company

Founded

2012

Specialties

research, life sciences, and biotechnology

Locations

Employees at Nurix Therapeutics

Updates

Today, at the American College of Rheumatology (ACR) Convergence 2024, we presented preclinical data in two posters demonstrating the potential superiority of our targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseases. The posters highlight preclinical data from two autoimmune and inflammatory disease programs: NX-5948, our proprietary, orally available, brain penetrant BTK degrader, and GS-6791, a selective, orally bioavailable degrader of IRAK4 which is being developed in collaboration with Gilead Sciences. Learn more here: https://bit.ly/48VUW87
We were honored to sponsor the The Leukemia & Lymphoma Society's Light The Night event in San Francisco, joining together to support those impacted by blood cancers. Our mission to develop innovative targeted protein modulation therapeutics to potentially improve the outcomes of those with cancer and other challenging diseases aligns closely with the purpose of this inspiring event—bringing hope, advancing research, and standing with patients and their families. We are grateful for our team members who came out to light the night and illuminate the path toward a brighter future for all affected by cancer. #LightTheNight
Nurix’s President and CEO, Arthur T. Sands, M.D., Ph.D., will discuss the latest company updates in a fireside chat at the the Stephens Biotechnology Virtual Fireside Chats on Thursday, November 14, 2024, at 2:30 p.m. ET. Be sure to tune in if you’re attending the conference.
Nurix’s Chief Scientific Officer, Gwenn Hansen, Ph.D., will discuss how Nurix is deploying its innovative targeted protein modulation platform to develop novel therapeutics in a presentation at the SMART Symposium on Wednesday, November 13, 2024, at 2:00 p.m. CST in Shenzhen, China. Learn more here: https://bit.ly/40wMGcq
Nurix’s Chief Financial Officer, Hans van Houte, and Chief Business Officer, Jason Kantor, Ph.D., will discuss the latest company updates in a fireside chat at the UBS Healthcare Conference on Tuesday, November 12, 2024, at 5:00 p.m. PT. Listen to the live or archived discussion here: https://lnkd.in/g-Bm2cR8
Nurix’s President and Chief Executive Officer, Arthur T. Sands, M.D., Ph.D., will participate in a panel discussion at the Truist BioPharma Symposium on Thursday, November 7, 2024, at 10:30 a.m. ET. Be sure to tune in if you’re attending the conference.
More than 234,000 people in the US will be diagnosed with lung cancer this year. At Nurix, we’re using our targeted protein modulation platform to potentially improve outcomes for those facing a diagnosis of cancer, including lung cancer. Learn more about our work here: https://bit.ly/3L7kMKK #LungCancerAwareness
Nurix’s Chief Business Officer, Jason Kantor, Ph.D., will share his experience in establishing major strategic partnerships during two panel sessions on Wednesday, October 30th at the 7th Annual TPD & Induced Proximity Summit. Learn more about the presentation and summit details here: https://bit.ly/47wOe7L
Nurix’s Chief Medical Officer, Paula OConnor , M.D., will discuss clinical findings from Nurix’s novel first-in-class BTK degrader, NX-5948, for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) at the 7th Annual TPD & Induced Proximity Summit on Wednesday, October 30th, at 9:00 a.m. ET. Learn more about the presentation and summit details here: https://bit.ly/47wOe7L

Join now to see what you are missing

Join now

Nurix Therapeutics | LinkedIn (original) (raw)

Biotechnology

San Francisco, CA 17,635 followers

Targeted protein degradation is only the beginning. Blazing a new path in medicine.

About us

Locations

Employees at Nurix Therapeutics

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding